Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07753655

The Value of Pretreatment With Letrozole on Induction Time of Medical Evacuation With Misoprostol in Cases of Missed Abortion

The aim is to evaluate the effect of letrozole pretreatment on the induction time during medical evacuation using misoprostol in women diagnosed with missed abortion, and to compare its efficacy and safety to misoprostol alone.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Letrozole

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women aged 18 - 45 years.
  • Diagnosed with missed abortion confirmed by ultrasound (absent fetal heartbeat and/or no embryonic development).
  • Gestational age ≤ 12 weeks based on last menstrual period
  • Hemoglobin levels >10 g/dL.
  • BMI ranging from 25 to 35 kg/m2.
  • Hemodynamically stable and no signs of infection.

Exclusion criteria

  • Incomplete abortion, inevitable abortion, or threatened miscarriage.
  • Suspected ectopic pregnancy and molar pregnancy.
  • History of allergy or contraindication to misoprostol or letrozole.
  • Coagulopathy or use of anticoagulant medications.
  • Chronic medical diseases (e.g., uncontrolled diabetes, cardiovascular disease, liver or renal dysfunction).
  • Prior uterine surgery that contraindicates medical abortion (e.g., classical cesarean section, myomectomy with uterine entry).
  • Uterine anomalies.
  • Women unsure of LMP

Treatment and study plan

Intervention Group: letrozole followed by misoprostol

Procedure

Group A (Intervention Group) will receive letrozole followed by misoprostol.

Control Group: misoprostol only

Procedure

Group B (Control Group) will receive misoprostol only, without prior letrozole pretreatment

Primary outcomes

  1. Time of complete uterine evacuation

    Time frame: one week following Misoprostol administration

    Time from misoprostol administration to complete uterine evacuation

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 7, 2026
Registry last updated
Aug 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.